Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR3.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR2.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR5.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR7.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR9.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR4.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR1.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR6.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR30.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR14.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR37.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR46.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR41.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR12.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR36.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR47.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR28.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR29.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR35.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR26.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR17.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR45.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR13.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR48.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR33.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR25.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR49.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR23.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR39.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR32.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR19.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR40.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR11.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR44.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR22.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR18.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR42.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR21.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR34.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR43.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR15.htm
EX-31.2 - EX-31.2 - ARIAD PHARMACEUTICALS INCd413091dex312.htm
EX-32.1 - EX-32.1 - ARIAD PHARMACEUTICALS INCd413091dex321.htm
EX-31.1 - EX-31.1 - ARIAD PHARMACEUTICALS INCd413091dex311.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR20.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR27.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR10.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR38.htm
10-Q - 10-Q - ARIAD PHARMACEUTICALS INCd413091d10q.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR8.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR24.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR31.htm
v2.4.0.6
Stock-Based Compensation
9 Months Ended
Sep. 30, 2012
Stock-Based Compensation
10. Stock-Based Compensation

The Company awards stock options and other equity-based instruments to its employees, directors and consultants and provides employees the right to purchase common stock at a discount (collectively “share-based payments”), pursuant to stockholder approved plans. The Company’s statement of operations included total compensation cost from share-based payments for the three and nine-month periods ended September 30, 2012 and 2011, as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
In thousands    2012      2011      2012      2011  

Compensation cost from:

           

Stock options

   $ 2,084       $ 609       $ 6,776       $ 2,215   

Stock and stock units

     1,697         971         5,343         3,589   

Purchases of common stock at a discount

     64         53         170         150   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 3,845       $ 1,633       $ 12,289       $ 5,954   
  

 

 

    

 

 

    

 

 

    

 

 

 

Compensation cost included in:

           

Research and development expenses

   $ 1,869       $ 822       $ 6,060       $ 2,927   

General and administrative expenses

     1,976         811         6,229         3,027   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 3,845       $ 1,633       $ 12,289       $ 5,954   
  

 

 

    

 

 

    

 

 

    

 

 

 

Stock Options

Stock options are granted with an exercise price equal to the closing market price of the Company’s common stock on the date of grant. Stock options generally vest ratably over four years and have contractual terms of ten years. Stock options are valued using the Black-Scholes option valuation model and compensation cost is recognized based on such fair value over the period of vesting on a straight-line basis.

Stock option activity under the Company’s stock plans for the nine months ended September 30, 2012 was as follows:

 

     Number of
Shares
    Weighted
Average

Exercise  Price
Per Share
 

Options outstanding, January 1, 2012

     7,381,329      $ 5.22   

Granted

     1,941,750      $ 15.36   

Forfeited

     (38,563   $ 11.91   

Exercised

     (1,737,863   $ 4.49   
  

 

 

   

Options outstanding, September 30, 2012

     7,546,653      $ 7.96   
  

 

 

   

Stock and Stock Unit Grants

Stock and stock unit grants are provided to non-employee directors as compensation and may include restrictions as to resale or other vesting provisions. Stock and stock unit grants are also awarded to employees and carry restrictions as to resale for periods of time or vesting provisions over time or based on performance measures as specified in the grant. Stock and stock unit grants are valued at the closing market price of the Company’s common stock on the date of grant and compensation expense is recognized over the requisite service period, vesting period or period during which restrictions remain on the common stock or stock units granted.

 

Stock and stock unit activity under the Company’s stock plans for the nine months ended September 30, 2012 was as follows:

 

     Number of
Shares
    Weighted
Average

Grant  Date
Fair Value
 

Outstanding, January 1, 2012

     2,785,026      $ 4.51   

Granted

     911,677      $ 15.02   

Forfeited

     (6,800   $ 4.13   

Vested or restrictions lapsed

     (1,551,242    $ 4.08   
  

 

 

   

Outstanding, September 30, 2012

     2,138,661      $ 9.31   
  

 

 

   

Included in stock and stock units outstanding in the above table are 392,500 performance share units, awarded in March 2011, that will vest if the Company receives regulatory approval of ponatinib from the U.S. Food and Drug Administration on or before December 31, 2016 and 352,000 performance share units, awarded in March 2012, that will vest if the Company receives regulatory approval of ponatinib from the European Medicines Agency on or before December 31, 2016. The number of shares that may vest, if any, related to the March 2012 awards is dependent on the timing of approval. The compensation costs for such performance-based stock awards will be based on the awards that ultimately vest and the grant date fair value of those awards. Compensation expense related to these performance share units will begin to be recognized when achievement of the performance condition is probable. The unrecognized stock compensation expense associated with the maximum number of shares that may be issued upon achievement of the performance conditions was $11.5 million at September 30, 2012.